Insuman Basal (Insulin Human (Rdna))

Insulin human is a recombinant form of human insulin that binds to insulin receptors on muscle, fat and liver cells. This binding activates signaling pathways that increase glucose uptake, promote glycogen synthesis, and suppress hepatic glucose output, thereby lowering blood glucose levels.

The dose of Insuman Basal is individualized by the prescribing healthcare professional based on factors such as the patient’s current glycemic control, body weight, diet, activity level, and concurrent medications. No standard dosing regimen is provided; the prescriber sets the appropriate amount.

Insuman Basal may be used during pregnancy or lactation only when the expected benefit to the mother outweighs potential risks to the fetus or infant. Healthcare providers should evaluate each case carefully and monitor blood glucose closely throughout pregnancy and while nursing.

To order Insuman Basal, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Insuman Basal is a recombinant human insulin with a prolonged absorption profile, similar in duration to other long‑acting insulins such as glargine or detemir. Compared with analogues, it may have a slightly different pharmacokinetic curve but offers comparable basal glucose control when dosed appropriately.

Insuman Basal must be stored in a refrigerator at 2‑8 °C. Keep the vial in its original carton, protect it from light, and avoid freezing or shaking. Once in use, the product may be kept at room temperature for a limited period as indicated in the package insert.

Insuman Basal is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated to reduce the risk of lipodystrophy. The exact timing and frequency are determined by the prescriber based on the patient’s insulin regimen.

The most serious risks include severe hypoglycemia, which can be life‑threatening if not treated promptly, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of hypoglycemia and to seek immediate medical assistance if a severe reaction occurs.

Insuman Basal should be avoided in individuals with a known hypersensitivity to recombinant human insulin or any of the excipients in the formulation. It is also contraindicated in patients experiencing severe hypoglycemia unawareness until the condition is corrected.